Fig. 9: Epigenetic modifications play crucial roles in lenvatinib resistance. | Cell Death & Disease

Fig. 9: Epigenetic modifications play crucial roles in lenvatinib resistance.

From: Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms

Fig. 9

The reported epigenetic mechanisms of lenvatinib resistance involve ncRNA regulation, RNA methylation/acetylation, and histone modification. NcRNAs promotes lenvatinib resistance through regulating PCD (e.g., lncRNA AC026401.3, lncMT1JP, lncRNA HOTAIRM1, miR-128-3p and circPIAS1), CSCs expansion (e.g., miR-183-5p, miR-3154, LCC-ZEB2-19 and circ0007386), metabolism reprogramming (e.g., LINC01532), and uncontrolled cell proliferation signaling pathway activity (e.g., CircCCNY and hsa-circ-0058046); key regulators of RNA methylation/acetylation include METTL3, METTL1, YTHDF2, and NAT10; histone modifications involve IGF2BP3-mediated lactylation and EZH2-dependent NOD2 methylation. Image created by Figdraw.

Back to article page